News

Advanced BioDesign Present Preclinical Result at 61st ASH Annual Meeting

Advanced BioDesign has presented a poster at the 61^st American Society of Hematology (ASH) Annual Meeting with their rational on its lead compound ABD-3001, as a treatment of patients with refractory or relapse Acute Myeloid Leukemia (r/r AML).

See poster

https://doi.org/10.1182/blood-2019-126484

More news

Advanced Biodesign, Winner of the France 2030 Plan's call for "I-Demo” Projects to Finance its "ODYSSEY" Clinical Trial With Up To €3M

Advanced BioDesign's winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments. As part of the France 2030 plan, the "i-Demo" scheme supports the development of highly innovative, high added-value products and services to strengthen France's scientific and technological capabilities.

Advanced BioDesign announces 14.3 million euros of additional funding from its main shareholder Xerys Invest

Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.